Q1 EPS Estimates for Mural Oncology Reduced by HC Wainwright

Mural Oncology plc (NASDAQ:MURA) – Analysts at HC Wainwright cut their Q1 2025 EPS estimates for Mural Oncology in a note issued to investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($2.13) for the quarter, down from their previous forecast of ($2.05). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Mural Oncology’s current full-year earnings is ($7.54) per share. HC Wainwright also issued estimates for Mural Oncology’s Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($5.65) EPS, FY2026 earnings at ($3.81) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at ($1.45) EPS.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period last year, the business posted ($3.57) EPS.

Mural Oncology Stock Performance

MURA stock opened at $3.90 on Monday. The stock has a market cap of $67.19 million, a P/E ratio of -0.43 and a beta of 3.66. The firm has a 50 day simple moving average of $3.87 and a 200 day simple moving average of $3.59. Mural Oncology has a 52 week low of $2.87 and a 52 week high of $5.12.

Institutional Trading of Mural Oncology

Several institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC boosted its holdings in shares of Mural Oncology by 1.4% during the fourth quarter. Squarepoint Ops LLC now owns 175,502 shares of the company’s stock worth $565,000 after purchasing an additional 2,470 shares during the period. Geode Capital Management LLC lifted its stake in Mural Oncology by 2.6% in the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after acquiring an additional 4,731 shares during the last quarter. Two Sigma Investments LP lifted its stake in Mural Oncology by 12.0% in the fourth quarter. Two Sigma Investments LP now owns 65,150 shares of the company’s stock valued at $210,000 after acquiring an additional 6,993 shares during the last quarter. Northern Trust Corp lifted its stake in Mural Oncology by 22.0% in the fourth quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock valued at $129,000 after acquiring an additional 7,197 shares during the last quarter. Finally, FMR LLC lifted its stake in Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after acquiring an additional 11,423 shares during the last quarter. 80.21% of the stock is currently owned by institutional investors and hedge funds.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.